Fig. 3

ERX-11 enhances palbociclib ability to reduce tumor growth in preclinical models of endocrine therapy resistance. a–d Following implantation and growth of ER+ tamoxifen-resistant xenografts (n = 4 tumors/group), mice were treated with vehicle, ERX-11 (10 mg/kg/day), palbociclib (50 mg/kg/day), or in combination. Tumor volume (a), body weight (b), and Ki-67 status of vehicle and drug-treated tumors were shown (c, d). Following implantation and growth of ER+ letrozole resistant xenografts (n = 7 tumors/group), mice were treated with vehicle or ERX-11(10 mg/kg/day), palbociclib (50 mg/kg/day), or in combination. Tumor volume (e), body weight (f), and Ki-67 status of vehicle and drug-treated tumors were shown (g, h) (*p < 0.05, ***p < 0.001, ****p < 0.0001)